- Beijing Tiantan reported a net income of 244.1 million yuan for the first quarter.
- The company’s revenue for the same period was 1.32 billion yuan.
- Analyst recommendations are overwhelmingly positive, with 14 buys, 0 holds, and 0 sells.
“`
A look at Beijing Tiantan Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tiantan Biological Products Corporation Limited, a company specializing in biological products, has garnered positive ratings in key areas according to the Smartkarma Smart Scores. With a strong focus on growth, the company has received a top score of 5 in this category, indicating promising prospects for expansion and development in the long term. Additionally, Beijing Tiantan Biological Products scores well in resilience and momentum, with scores of 4 in both categories, showcasing its ability to adapt to challenges and maintain a positive trajectory in the market.
While the company shows promise in growth, it has received moderate scores of 2 in both the value and dividend categories. This suggests that investors looking for value or dividend income may need to carefully evaluate Beijing Tiantan Biological Products‘ financial performance and strategies before investing. Overall, the company’s focus on researching, developing, and commercializing biological products, specifically in the treatment of hepatitis and vaccine products, positions it well for future success in the competitive healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
